Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
Journal: Neurology
Published: May 27, 2017
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
Journal: Journal of Alzheimer's disease : JAD
Published: September 03, 2016
Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease.
Journal: Current Alzheimer research
Published: June 09, 2016
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
Journal: Alzheimer's research & therapy
Published: March 09, 2016
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Journal: Alzheimer's research & therapy
Published: February 03, 2016
Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study.
Journal: The journal of prevention of Alzheimer's disease
Published: January 01, 2016
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Journal: Neurology
Published: November 25, 2014
Showing 1-7 of 7
Last Updated: 09/26/2026